Success Metrics

Clinical Success Rate
71.4%

Based on 15 completed trials

Completion Rate
71%(15/21)
Active Trials
1(4%)
Results Posted
47%(7 trials)
Terminated
6(26%)

Phase Distribution

Ph phase_2
10
43%
Ph not_applicable
1
4%
Ph phase_1
9
39%
Ph phase_3
2
9%

Phase Distribution

9

Early Stage

10

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
9(40.9%)
Phase 2Efficacy & side effects
10(45.5%)
Phase 3Large-scale testing
2(9.1%)
N/ANon-phased studies
1(4.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

15 of 21 finished

Non-Completion Rate

28.6%

6 ended early

Currently Active

1

trials recruiting

Total Trials

23

all time

Status Distribution
Active(2)
Completed(15)
Terminated(6)

Detailed Status

Completed15
Terminated6
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
1
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (40.9%)
Phase 210 (45.5%)
Phase 32 (9.1%)
N/A1 (4.5%)

Trials by Status

completed1565%
not_yet_recruiting14%
terminated626%
recruiting14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT06529731Phase 2

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
NCT04979052Phase 2

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Completed
NCT06381661Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not Yet Recruiting
NCT03747484Phase 1

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
NCT02666768Phase 2

ACTIMMUNE in Intermediate Osteopetrosis

Completed
NCT01468337Phase 1

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Completed
NCT03063632Phase 2

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Completed
NCT00001112Phase 1

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

Completed
NCT00001004Phase 2

A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex

Completed
NCT00000761Phase 1

Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

Completed
NCT01965327Phase 2

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Completed
NCT03548818

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Completed
NCT02338973Phase 1

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Terminated
NCT01376362Phase 1

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

Completed
NCT00012467Phase 2

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Completed
NCT00076635Phase 3

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Terminated
NCT00043303Phase 2

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

Completed
NCT00043342Phase 1

Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

Completed
NCT00057447Phase 1

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Terminated
NCT00043316Phase 1

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23